Drug Profile

Tretinoin lotion - Bausch Health/Ortho Dermatologics

Alternative Names: ALTRENO; IDP 121

Latest Information Update: 30 Oct 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Valeant Pharmaceuticals International
Developer Bausch Health Companies; Ortho Dermatologics
Class Antiacnes; Antineoplastics; Cyclohexenes; Keratolytics; Retinoids; Small molecules
Mechanism of Action Protein synthesis inhibitors; Retinoic acid receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Marketed Acne vulgaris

Most Recent Events

13 Jan 2020 Pooled efficacy and safety data from two phase III trials in Acne vulgaris released by Ortho Dermatologics
12 Nov 2018 Chemical structure information added
30 Oct 2018 Launched for Acne vulgaris (In adolescents, In children, In adults) in USA (Topical)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com